Hims & Hers Health, Inc. (NYSE:HIMS) Stock Has Consensus Price Target of $32.43

Hims & Hers Health, Inc. (NYSE:HIMS) has been given a consensus recommendation of “Hold” by the sixteen analysts that are covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, twelve have assigned a hold recommendation and three have given a buy recommendation to the company. The average twelve-month target price among brokerages that have covered the stock in the last year is $32.43.

HIMS has been the subject of several recent research reports. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Wall Street Zen raised shares of Hims & Hers Health from a “sell” rating to a “hold” rating in a report on Saturday, August 15th. Morgan Stanley raised their price target on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Hims & Hers Health in a report on Friday, August 7th. Finally, Barclays decreased their price objective on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating for the company in a research report on Friday, August 21st.

Hims & Hers Health Stock Down 0.4%

Shares of HIMS opened at $28.65 on Friday. The company has a market capitalization of $6.68 billion, a price-to-earnings ratio of -45.48 and a beta of 2.42. Hims & Hers Health has a 52 week low of $13.74 and a 52 week high of $65.30. The stock’s 50-day moving average price is $29.37 and its 200-day moving average price is $28.17. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company had revenue of $753.21 million for the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the business posted $0.17 earnings per share. The firm’s revenue was up 38.2% compared to the same quarter last year. On average, sell-side analysts predict that Hims & Hers Health will post -0.16 EPS for the current year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Neutral Sentiment: The announcements largely concern the same lawsuit rather than multiple separate cases. Investors who purchased HIMS securities between August 4, 2025, and July 29, 2026, are being encouraged to seek lead-plaintiff status before the November 2, 2026 deadline. Kaplan Fox class action announcement
• Negative Sentiment: The lawsuit stems from allegations that Hims and its executives made material misstatements or omissions concerning the company’s privacy practices and other business conduct. The claims reportedly follow a Federal Trade Commission complaint accusing Hims of serious misconduct; these allegations have not been proven in court. Potential litigation costs, regulatory scrutiny, reputational damage, and uncertainty over investor recoveries create a negative overhang for the stock. Hagens Berman HIMS class action announcement

Insiders Place Their Bets

In other Hims & Hers Health news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $28.39, for a total value of $398,226.53. Following the sale, the chief operating officer directly owned 456,660 shares of the company’s stock, valued at approximately $12,964,577.40. This trade represents a 2.98% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Soleil Boughton sold 25,111 shares of the business’s stock in a transaction that occurred on Wednesday, August 19th. The shares were sold at an average price of $27.55, for a total value of $691,808.05. Following the completion of the sale, the insider owned 313,964 shares of the company’s stock, valued at $8,649,708.20. This trade represents a 7.41% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 128,684 shares of company stock worth $3,731,869 in the last 90 days. 11.76% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. QRG Capital Management Inc. purchased a new stake in Hims & Hers Health in the 2nd quarter worth $248,000. Envestnet Portfolio Solutions Inc. raised its position in Hims & Hers Health by 46.9% during the second quarter. Envestnet Portfolio Solutions Inc. now owns 32,469 shares of the company’s stock worth $1,126,000 after acquiring an additional 10,366 shares during the period. Bienville Capital Management LLC purchased a new position in Hims & Hers Health during the second quarter valued at $27,242,000. Engineers Gate Manager LP purchased a new position in Hims & Hers Health during the second quarter valued at $232,000. Finally, Integrated Wealth Concepts LLC purchased a new position in Hims & Hers Health during the second quarter valued at $147,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides access to personalized care through digital platforms, including the Hims and Hers brands. The company connects consumers with licensed healthcare professionals for online consultations, treatment plans and prescription medications, where appropriate.

Its services address areas such as sexual health, hair loss, skin care, mental health, weight management and primary care. Hims & Hers also offers over-the-counter products, supplements and personal-care items, with products and prescriptions delivered directly to customers through its fulfillment network and pharmacy partners.

The company was established in 2016 and initially focused on men’s health before expanding under the Hers brand to serve women and broaden its health-care offerings.